- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02704299
The Study of Surgery,Chemotherapy and Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.
March 9, 2016 updated by: Cellular Biomedicine Group Ltd.
A Single-centered Clinical Trial of Surgery,Chemotherapy in Combination With Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.
Evaluate the feasibility ,safety and efficacy of Surgery,Chemotherapy in Combination with Autologous T cells-Based Immunotherapy for Advanced Gastric Cancer.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Safety:AE/SAE Efficacy:immunologic function;FPS
Study Type
Interventional
Enrollment (Anticipated)
36
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jiafu / Ji, Doctor
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 78 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged between 18 to 80 years, males and females.
- Subjects who understand and sign the consent form for this study.
- The pathologically confirmed advanced gastric cancer T3、T4 or T2 and Metastasis in lymph nodes.
- Subjects are surgical candidates.
- No distant metastasis (M0) and No distant lymph node metastasis.
- Expected survival time of at least 6 months.
Exclusion Criteria:
- Subjects who do not sign the consent form for this study.
- The subject has an allergic history of medicine or food.
- The subject has uncontrolled or hard-to-control diseases of cardiovascular,liver,kidney or lung,endocrine system.
- The subject tests positive for: HIV, hepatitis virus, syphilis or other infectious diseases.
- The subject has an history of other malignant tumour.
- The subject has history of alcoholism, drug abuse, or mental illness in the 12 years prior to this trial.
- The subject has participated in any other clinical trial in the 3 months prior to this trial.
- The subject is pregnant, lactating or planning to conceive within the next 24 months.
- The subject has any other unsuitable or adverse condition to be determined by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Autologous T cells-Based Immunotherapy
Surgery Chemotherapy Autologous T cells-Based Immunotherapy
|
TCM cells are the subpopulation of T lymphocytes with key characteristics including high potency and long-term memory of specific immunity.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free-Survival(PFS)
Time Frame: 24months
|
The primary objective is to assess progression free survival (PFS).
|
24months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidences of adverse events or serious adverse events
Time Frame: 24months
|
24months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: / / /, /
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2016
Primary Completion (Anticipated)
June 1, 2018
Study Completion (Anticipated)
September 1, 2018
Study Registration Dates
First Submitted
February 26, 2016
First Submitted That Met QC Criteria
March 4, 2016
First Posted (Estimate)
March 10, 2016
Study Record Updates
Last Update Posted (Estimate)
March 11, 2016
Last Update Submitted That Met QC Criteria
March 9, 2016
Last Verified
March 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CBMG-TCM-GC-1.1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer.
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on Autologous T cells-Based Immunotherapy
-
King's College LondonImperial College London; Medical Research Council; Guy's and St Thomas' NHS Foundation... and other collaboratorsUnknownCrohn Disease
-
Beijing Friendship HospitalNewish Technology (Beijing) Co., Ltd.UnknownCarcinoma, Non-Small-Cell LungChina
-
The Second Hospital of Nanjing Medical UniversityUnknownNasopharyngeal NeoplasmsChina
-
University of PennsylvaniaCompleted
-
Hebei Senlang Biotechnology Inc., Ltd.Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei HospitalRecruitingLymphoma | Leukemia | Multiple Myeloma of Bone (Diagnosis)China
-
The Nordic Network For Clinical Islet TransplantationActive, not recruiting
-
The First Affiliated Hospital of Nanchang UniversityUnknownRelapsed or Refractory Multiple MyelomaChina
-
AdaptimmuneCompletedCarcinoma | Non-Small Cell Lung CancerUnited States, Spain, United Kingdom, Canada
-
King's College Hospital NHS TrustRecruiting